← Back to Treatments
🏅 FDA Orphan Designation

MIPLYFFA

ARIMOCLOMOL CITRATE

Manufacturer: Acer Therapeutics Inc.

Indicated for:
Niemann-Pick disease type C, adult neurologic onset

FDA-Approved Indications (1)

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and old…

Population: adult and pediatric patients ≥2 years

Indications & Usage

1 INDICATIONS AND USAGE MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. ( 1 )

💙 Support Programs

View all →
MIPLYFFA
Acer Therapeutics Inc.
MIPLYFFA
Acer Therapeutics Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.